Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.
| Drug | TSG | SLP (drug target) | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | # |
|---|---|---|---|---|---|---|---|---|---|---|
| sunitinib | FBXW7 | KIT | 7 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | FBXW7 | KIT | 4 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | FBXW7 | RET | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | FBXW7 | KIT | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | FBXW7 | RET | 4 | |||||||
| crizotinib | FBXW7 | ALK | 7 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FBXW7 | KIT | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FBXW7 | ALK | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FBXW7 | RET | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FBXW7 | WEE1 | 3 | |||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | FBXW7 | TOP1MT | 3 | |||||||
| lurbinectedin, irinotecan | FBXW7 | TOP1MT | 3 | |||||||
| nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone | FBXW7 | RXRB | 3 | |||||||
| pembrolizumab, belzutifan, lenvatinib | FBXW7 | KIT | 3 | |||||||
| pembrolizumab, belzutifan, lenvatinib | FBXW7 | RET | 3 | |||||||
| avapritinib | FBXW7 | KIT | 7 | |||||||
| pazopanib | FBXW7 | KIT | 7 | |||||||
| regorafenib | FBXW7 | KIT | 7 | |||||||
| regorafenib | FBXW7 | RET | 7 | |||||||
| selinexor | FBXW7 | XPO1 | 7 | |||||||
| adavosertib, radiation therapy | FBXW7 | WEE1 | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | FBXW7 | ALK | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | FBXW7 | RET | 2 | |||||||
| alectinib, stereotactic radiosurgery | FBXW7 | ALK | 2 | |||||||
| alvocidib, paclitaxel | FBXW7 | CDK9 | 2 | |||||||
| alvocidib, paclitaxel | FBXW7 | CDK1 | 2 | |||||||
| apatinib, irinotecan | FBXW7 | TOP1MT | 2 | |||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | FBXW7 | TOP1MT | 2 | |||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | FBXW7 | TOP1MT | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | FBXW7 | KIT | 2 | |||||||
| biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging | FBXW7 | TLR9 | 2 | |||||||
| bortezomib | FBXW7 | PSMB5 | 2 | |||||||
| bryostatin 1, paclitaxel | FBXW7 | PRKCE | 2 | |||||||
| cabozantinib | FBXW7 | RET | 2 | |||||||
| cabozantinib, atezolizumab, cabozantinib, cabozantinib | FBXW7 | RET | 2 | |||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | FBXW7 | CA3 | 2 | |||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | FBXW7 | TOP1MT | 2 | |||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | FBXW7 | CA3 | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | FBXW7 | ALK | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | FBXW7 | RET | 2 | |||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | FBXW7 | HDAC3 | 2 | |||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | FBXW7 | KIT | 2 | |||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | FBXW7 | RET | 2 | |||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | FBXW7 | TOP1MT | 2 | |||||||
| irinotecan, capecitabine | FBXW7 | TOP1MT | 2 | |||||||
| irinotecan, docetaxel | FBXW7 | TOP1MT | 2 | |||||||
| laboratory biomarker analysis, oxaliplatin, pralatrexate | FBXW7 | FPGS | 2 | |||||||
| lenvatinib, pembrolizumab | FBXW7 | KIT | 2 | |||||||
| lenvatinib, pembrolizumab | FBXW7 | RET | 2 | |||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | FBXW7 | KIT | 2 | |||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | FBXW7 | RET | 2 | |||||||
| ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab | FBXW7 | TOP1MT | 2 | |||||||
| melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells | FBXW7 | CHRNB4 | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | FBXW7 | KIT | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | FBXW7 | RET | 2 | |||||||
| motexafin gadolinium, radiation therapy | FBXW7 | TXNRD1 | 2 | |||||||
| ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine | FBXW7 | TOP2A | 2 | |||||||
| olaparib | FBXW7 | PARP3 | 2 | |||||||
| pembrolizumab, guadecitabine, mocetinostat | FBXW7 | HDAC3 | 2 | |||||||
| pembrolizumab, lenvatinib | FBXW7 | KIT | 2 | |||||||
| pembrolizumab, lenvatinib | FBXW7 | RET | 2 | |||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | FBXW7 | KIT | 2 | |||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | FBXW7 | RET | 2 | |||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | FBXW7 | TOP1MT | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | FBXW7 | KIT | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | FBXW7 | RET | 2 | |||||||
| pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography | FBXW7 | FPGS | 2 | |||||||
| quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery | FBXW7 | RET | 2 | |||||||
| regorafenib, laboratory biomarker analysis | FBXW7 | KIT | 2 | |||||||
| regorafenib, laboratory biomarker analysis | FBXW7 | RET | 2 | |||||||
| rituximab | FBXW7 | MS4A1 | 2 | |||||||
| sorafenib, administered orally, ct/mri | FBXW7 | KIT | 2 | |||||||
| sorafenib, administered orally, ct/mri | FBXW7 | RET | 2 | |||||||
| topotecan | FBXW7 | TOP1MT | 2 | |||||||
| arsenic trioxide | FBXW7 | TXNRD1 | 7 | |||||||
| carfilzomib | FBXW7 | PSMB5 | 7 | |||||||
| carfilzomib | FBXW7 | PSMB2 | 7 | |||||||
| selpercatinib | FBXW7 | RET | 7 | |||||||
| sorafenib | FBXW7 | KIT | 7 | |||||||
| sorafenib | FBXW7 | RET | 7 | |||||||
| vandetanib | FBXW7 | RET | 7 | |||||||
| 18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography | FBXW7 | PARP3 | 1 | |||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | FBXW7 | HDAC3 | 1 | |||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) | FBXW7 | TLR9 | 1 | |||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | FBXW7 | HDAC3 | 1 | |||||||
| 3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide | FBXW7 | TXNRD1 | 1 | |||||||
| 5 fluorouracil, leucovorin, irinotecan, oxaliplatin | FBXW7 | TOP1MT | 1 | |||||||
| 9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | FBXW7 | TOP1MT | 1 | |||||||
| acetazolamide, temozolomide | FBXW7 | CA3 | 1 | |||||||
| acetazolamide, temozolomide | FBXW7 | CA14 | 1 | |||||||
| actidose aqua, artesunate, amodiaquine | FBXW7 | HNMT | 1 | |||||||
| adavosertib | FBXW7 | WEE1 | 1 | |||||||
| adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy | FBXW7 | WEE1 | 1 | |||||||
| adavosertib, radiation therapy, temozolomide | FBXW7 | WEE1 | 1 | |||||||
| adebrelimab injection, apatinib mesylate tablets, carboplatin, cisplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| adebrelimab, apatinib mesylate, etoposide, carboplatin | FBXW7 | TOP2A | 1 | |||||||
| adebrelimab, carboplatin/cisplatin, etoposide, radiation therapy | FBXW7 | TOP2A | 1 | |||||||
| adebrelimab, radiation therapy, etoposide, carboplatin(ec) | FBXW7 | TOP2A | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | FBXW7 | PARP3 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | FBXW7 | KIT | 1 | |||||||
| afatinib, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| aldoxorubicin, topotecan | FBXW7 | TOP1MT | 1 | |||||||
| aldoxorubicin, topotecan | FBXW7 | TOP2A | 1 | |||||||
| alvocidib, docetaxel | FBXW7 | CDK9 | 1 | |||||||
| alvocidib, docetaxel | FBXW7 | CDK1 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | FBXW7 | CDK9 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | FBXW7 | CDK1 | 1 | |||||||
| amifostine trihydrate, cisplatin, etoposide, radiation therapy | FBXW7 | TOP2A | 1 | |||||||
| aminolevulinic acid | FBXW7 | ALAD | 1 | |||||||
| aminolevulinic acid, surgical resection | FBXW7 | ALAD | 1 | |||||||
| amrubicin | FBXW7 | TOP2A | 1 | |||||||
| amrubicin, cisplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| amrubicin, topotecan | FBXW7 | TOP1MT | 1 | |||||||
| amrubicin, topotecan | FBXW7 | TOP2A | 1 | |||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | FBXW7 | TOP1MT | 1 | |||||||
| anti-igf-1r recombinant monoclonal antibody mk-0646, cisplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | FBXW7 | ALK | 1 | |||||||
| arsenic trioxide, radiation therapy | FBXW7 | TXNRD1 | 1 | |||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | FBXW7 | TXNRD1 | 1 | |||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | FBXW7 | EGLN3 | 1 | |||||||
| at-101, topotecan | FBXW7 | TOP1MT | 1 | |||||||
| atezolizumab, cabozantinib | FBXW7 | RET | 1 | |||||||
| atezolizumab, carboplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| atezolizumab, tivozanib | FBXW7 | KIT | 1 | |||||||
| atorvastatin, temozolomide, radiotherapy | FBXW7 | NR1I3 | 1 | |||||||
| autologous dendritic cell-adenovirus p53 vaccine, carboplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| avapritinib, midazolam | FBXW7 | KIT | 1 | |||||||
| avastin, bortezomib | FBXW7 | PSMB5 | 1 | |||||||
| avastin, temozolomide, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| avastin, temozolomide, radiation therapy (xrt), irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| avelumab, irinotecan, paclitaxel, best supportive care (bsc) | FBXW7 | TOP1MT | 1 | |||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | FBXW7 | HDAC3 | 1 | |||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | FBXW7 | MS4A1 | 1 | |||||||
| azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine | FBXW7 | TOP1MT | 1 | |||||||
| azd1775, olaparib | FBXW7 | PARP3 | 1 | |||||||
| bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 | FBXW7 | TOP1MT | 1 | |||||||
| becatecarin | FBXW7 | TOP2A | 1 | |||||||
| belinostat, cisplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| belotecan, etoposide, cisplatin | FBXW7 | TOP2A | 1 | |||||||
| bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | FBXW7 | TOP1MT | 1 | |||||||
| berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging | FBXW7 | TOP1MT | 1 | |||||||
| bevacizumab [avastin], fotemustine | FBXW7 | TXNRD1 | 1 | |||||||
| bevacizumab [avastin], irinotecan, temozolomide | FBXW7 | TOP1MT | 1 | |||||||
| bevacizumab, cediranib, cediranib maleate, olaparib | FBXW7 | PARP3 | 1 | |||||||
| bevacizumab, cisplatin, etoposide, radiation therapy | FBXW7 | TOP2A | 1 | |||||||
| bevacizumab, dasatinib, placebo | FBXW7 | KIT | 1 | |||||||
| bevacizumab, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging | FBXW7 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, radiation therapy (xrt), topotecan | FBXW7 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, vorinostat | FBXW7 | HDAC3 | 1 | |||||||
| bi 764532, carboplatin, etoposide, atezolizumab, durvalumab, cisplatin | FBXW7 | TOP2A | 1 | |||||||
| bi 764532, topotecan, single agent chemotherapy | FBXW7 | TOP1MT | 1 | |||||||
| binimetinib, hydroxychloroquine | FBXW7 | TLR9 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib | FBXW7 | KIT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin | FBXW7 | TOP1MT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | FBXW7 | KIT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | FBXW7 | RET | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib | FBXW7 | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab | FBXW7 | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, crizotinib, radiologic examination | FBXW7 | ALK | 1 | |||||||
| biopsy, folfirinox, ciprofloxacin, metronidazole, pembrolizumab, surgical resection | FBXW7 | TOP2A | 1 | |||||||
| biopsy, magnetic resonance imaging, radiation therapy, selinexor | FBXW7 | XPO1 | 1 | |||||||
| biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab | FBXW7 | TOP1MT | 1 | |||||||
| biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration | FBXW7 | PARP3 | 1 | |||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | FBXW7 | KIT | 1 | |||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | FBXW7 | RET | 1 | |||||||
| biospecimen collection, magnetic resonance imaging, selinexor, temozolomide | FBXW7 | XPO1 | 1 | |||||||
| bl-b01d1, irinotecan, paclitaxel, docetaxel | FBXW7 | TOP1MT | 1 | |||||||
| bl-b01d1, topotecan | FBXW7 | TOP1MT | 1 | |||||||
| bms-833923, carboplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| bms-986012, carboplatin, etoposide, nivolumab | FBXW7 | TOP2A | 1 | |||||||
| bms-986012, cisplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| bms-986012, cisplatin, etoposide, platinum, carboplatin | FBXW7 | TOP2A | 1 | |||||||
| bms-986489 (bms-986012+nivolumab), atezolizumab, carboplatin, etoposide | FBXW7 | TOP2A | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | FBXW7 | TOP1MT | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | FBXW7 | TOP2A | 1 | |||||||
| bortezomib, carboplatin, paclitaxel | FBXW7 | PSMB5 | 1 | |||||||
| bortezomib, gemcitabine hydrochloride | FBXW7 | PSMB5 | 1 | |||||||
| bortezomib, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| bortezomib, irinotecan | FBXW7 | PSMB5 | 1 | |||||||
| bortezomib, radiation therapy | FBXW7 | PSMB5 | 1 | |||||||
| bortezomib, temozolomide, pharmacological study | FBXW7 | PSMB5 | 1 | |||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | FBXW7 | CA3 | 1 | |||||||
| cabozantinib, durvalumab, tremelimumab | FBXW7 | RET | 1 | |||||||
| cabozantinib, nivolumab | FBXW7 | RET | 1 | |||||||
| cabozantinib, pembrolizumab | FBXW7 | RET | 1 | |||||||
| camrelizumab, docetaxel, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib | FBXW7 | TOP1MT | 1 | |||||||
| capecitabine, carboplatin, cisplatin, etoposide, laboratory biomarker analysis, temozolomide | FBXW7 | TOP2A | 1 | |||||||
| capecitabine, cisplatin, epirubicin, gemcitabine | FBXW7 | TOP2A | 1 | |||||||
| capecitabine, epirubicin, amg 102, cisplatin, placebo | FBXW7 | TOP2A | 1 | |||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | FBXW7 | PARP3 | 1 | |||||||
| capecitabine, oxaliplatin, irinotecan | FBXW7 | TOP1MT | 1 | |||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | FBXW7 | HDAC3 | 1 | |||||||
| carboplatin, atezolizumab, etoposide, total body irradiation, hypofractionated radiation therapy, magnetic resonance imaging | FBXW7 | TOP2A | 1 | |||||||
| carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, mesna, vincristine sulfate, radiation therapy | FBXW7 | TOP2A | 1 | |||||||
| carboplatin, cisplatin, docetaxel, etoposide, pembrolizumab | FBXW7 | TOP2A | 1 | |||||||
| carboplatin, cisplatin, etoposide, irinotecan hydrochloride, radiation therapy | FBXW7 | TOP2A | 1 | |||||||
| carboplatin, cisplatin, etoposide, sintilimab, ibi110 | FBXW7 | TOP2A | 1 |